|Articles|July 1, 2001

July 2001
Volume 7
Issue 7

Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans

Author(s)Michael E. Chernew, PhD, Dean G. Smith, PhD, Duane M. Kirking, PharmD, PhD

Download PDF: Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans

Articles in this issue

about 25 years ago

Article

Electronic Prescribing in Ambulatory Practice: Promises, Pitfalls, and Potential Solutions

about 25 years ago

Article

Another Theory About Healthcare Expenditures and Inflation Refuted by the Facts

about 25 years ago

Article

Economic Evaluation of Lamivudine Compared with Interferon-Alpha in the Treatment of Chronic Hepatitis B in the United States

about 25 years ago

Article

Promoting Smoking Abstinence in Pregnant and Postpartum Patients: A Comparison of Two Approaches

about 25 years ago

Article

Primary Care Physician Job Satisfaction and Turnover

about 25 years ago

Article

Physician Characteristics and the Initiation of Beta-Adrenergic Blocking Agent Therapy After Acute Myocardial Infarction in a Managed Care Population

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD